Transform Pharmaceuticals Inc

AMAG Pharmaceuticals is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company has two commercial products, Feridex I.V. and GastroMARK, both of which are imaging agents that are approved and marketed in the United States, Europe and other countries. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease. Combidex, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from normal lymph nodes. AMAG Pharmaceuticals corporate and executive offices are located in Cambridge, Mass.

Kiniksa Pharmaceuticals is a biopharmaceutical company dedicated to addressing critical therapeutic needs for patients suffering from debilitating diseases. With a focus on immunemodulating assets, Kiniksa approaches its mission with a sense of urgency, understanding that every moment counts in the pursuit of better health outcomes. Headquartered in Lexington, Massachusetts, Kiniksa operates internationally with locations in the United Kingdom and Switzerland. The company emphasizes patient advocacy and strives to make every second matter in the development of innovative treatments for conditions such as recurrent pericarditis. Generated from the website

KALA BIO is a clinical-stage biopharmaceutical company based in Waltham, MA, dedicated to addressing rare and serious eye diseases through innovative therapies. Utilizing their proprietary mesenchymal stem cell secretome (MSC-S) platform, the company aims to develop regenerative treatments to preserve vision and improve patient outcomes. The firm is currently advancing its pipeline with therapies like KPI-012, a topical treatment for persistent corneal epithelial defect (PCED), and KPI-014, an intravitreal therapy for inherited retinal diseases. With a strong focus on biologics following the sale of its commercial products, KALA BIO is committed to making significant advancements in ophthalmic care. Generated from the website